During the last three months, 9 analysts shared their evaluations of Nurix Therapeutics (NASDAQ:NRIX), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 3 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 5 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $31.67, a high estimate of $41.00, and a low estimate of $26.00. This upward trend is evident, with the current average reflecting a 11.12% increase from the previous average price target of $28.50.
Diving into Analyst Ratings: An In-Depth Exploration
A comprehensive examination of how financial experts perceive Nurix Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Etzer Darout | BMO Capital | Announces | Outperform | $35.00 | - |
| Gil Blum | Needham | Maintains | Buy | $29.00 | $29.00 |
| David Dai | UBS | Announces | Buy | $35.00 | - |
| Gil Blum | Needham | Maintains | Buy | $29.00 | $29.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $30.00 | $26.00 |
| Gregory Renza | RBC Capital | Lowers | Outperform | $26.00 | $27.00 |
| Sudan Loganathan | Stephens & Co. | Maintains | Overweight | $31.00 | $31.00 |
| Gil Blum | Needham | Maintains | Buy | $29.00 | $29.00 |
| Roger Song | Jefferies | Announces | Buy | $41.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nurix Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nurix Therapeutics compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
For valuable insights into Nurix Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Nurix Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Nurix Therapeutics
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Nurix Therapeutics: Financial Performance Dissected
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Nurix Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 31 August, 2024, the company experienced a revenue decline of approximately -31.84%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Nurix Therapeutics's net margin excels beyond industry benchmarks, reaching -388.91%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Nurix Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -13.1%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Nurix Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -9.56%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Nurix Therapeutics's debt-to-equity ratio is below the industry average at 0.07, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: Simplified
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
